Miłosz Szczotka

Miłosz Szczotka

Auto-generated profile, based on publicly available information

Miłosz Szczotka


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MTMateusz Trubalski
Mateusz Trubalski
AMAgnieszka Anna Markiewicz-Gospodarek
Agnieszka Anna Markiewicz-Gospodarek
MŻMarta Żerebiec
Marta Żerebiec
JPJulia Poleszak
Julia Poleszak
MSMiłosz Szczotka
Miłosz Szczotka
SSSylwia Edyta Szymańczyk
Sylwia Edyta Szymańczyk
Schizophrenia is a complex neuropsychiatric disorder characterized by a diverse range of symptoms, including positive, negative symptoms such as alogia, anhedonia, avolition, and affective flattening, cognitive symptoms, and emotional symptoms as a separate domain. Emerging evidence suggests that oxidative stress and neuroinflammation play crucial roles in the etiopathogenesis of schizophrenia. The aim of this review is the interplay between oxidative stress—defined as an imbalance between reactive oxygen species (ROS) production and antioxidant defenses—and neuroinflammatory processes within the central nervous system. Studies indicate that elevated levels of oxidative markers and pro-inflammatory cytokines are commonly observed in individuals with schizophrenia, pointing to a potential pathophysiological link. The dysregulation of redox homeostasis may exacerbate neuroinflammatory responses, contributing to neuronal damage and the subsequent manifestation of psychiatric symptoms. Furthermore, genetic and environmental factors may interact with these biological processes, influencing individual susceptibility to schizophrenia. Understanding the mechanisms by which oxidative stress and neuroinflammation contribute to the development and progression of schizophrenia could pave the way for novel therapeutic strategies aimed at mitigating these pathological processes and improving patient outcomes.

25 July 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MGMonika Grudzień
Monika Grudzień
ANAleksandra Nowińska
Aleksandra Nowińska
AGAnna Gryc
Anna Gryc
JLJakub Lipiec
Jakub Lipiec
AGAleksandra Gradek
Aleksandra Gradek
MSMiłosz Szczotka
Miłosz Szczotka
For a considerable length of time, artificial sweeteners have been seen as safe dietary ingredients, promoting weight control and regulating blood sugar levels. However, a growing number of scientific studies are questioning their supposed biological neutrality. Current analyses suggest that some of these substances may affect the composition and function of the gut microbiota, which in turn may affect the immune system and play a role in the development of chronic inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. There is growing evidence of a potential link between long-term intake of artificial sweeteners and the onset of insulin resistance and type 2 diabetes. In addition, it has been noted that frequent consumption of artificially sweetened beverages may be associated with an increased risk of stroke, cardiovascular disease and higher overall mortality, especially among overweight or obese postmenopausal women. These substances are commonly used in protein supplements, energy drinks and sports supplements, which may also affect important post-exercise recovery processes - including inflammation, insulin regulation, gut function and hydration status. These observations highlight the need for further interdisciplinary research into the long-term effects of artificial sweeteners on metabolic health and overall body function, especially in groups with high levels of consumption, such as people with metabolic syndrome and patients with type 2 diabetes.